VIA
IART icon

Vident Investment Advisory’s Integra LifeSciences IART Stock Holding History

Vident Investment Advisory’s Portfolio IART Stock Details IART Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-24,942
Closed -$743K – 590
2015
Q3 		$743K Sell
24,942
-4,259
-15% -$133K 0.1% 302
2015
Q2 		$804K Buy
29,201
+1,766
+6% +$47.1K 0.11% 244
2015
Q1 		$691K Buy
+27,435
New +$649K 0.14% 210

Other funds holding IART

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
CIP
Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
VNIM
Vaughan Nelson Investment Management Houston, Texas $11.3B AUM 53% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
SAM
Silvercrest Asset Management New York $13.8B AUM 28.39% 1-Year Est. Return

Vident Investment Advisory's IART Position: Q4 2015 in Review

Vident Investment Advisory sold out of Integra LifeSciences (IART) in Q4 2015, closing a stake of 24,942 shares — an estimated $743K sold.

Vident Investment Advisory first reported a position in IART in Q1 2015 and held it in 3 quarters. The position peaked at $804K in Q2 2015. 186 funds tracked by Wall St. Rank hold IART as of Q4 2015.

  • Vident Investment Advisory reported no remaining Integra LifeSciences position as of Q4 2015 after selling out during the quarter.
  • Vident Investment Advisory sold 24,942 Integra LifeSciences shares in Q4 2015, an estimated $743K.
  • Vident Investment Advisory first reported a position in Integra LifeSciences in Q1 2015 and held it in 3 quarters.
  • Vident Investment Advisory's Integra LifeSciences position peaked at $804K in Q2 2015.
  • 186 funds tracked by Wall St. Rank held Integra LifeSciences as of Q4 2015.

Based on Vident Investment Advisory's 13F filing for Q4 2015, filed 17 Feb 2016.